These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 17637810

  • 1. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
    Golay J, Cuppini L, Leoni F, Micò C, Barbui V, Domenghini M, Lombardi L, Neri A, Barbui AM, Salvi A, Pozzi P, Porro G, Pagani P, Fossati G, Mascagni P, Introna M, Rambaldi A.
    Leukemia; 2007 Sep; 21(9):1892-900. PubMed ID: 17637810
    [Abstract] [Full Text] [Related]

  • 2. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.
    Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G, Mascagni P, Lübbert M, Dello Sbarba P, Santini V.
    Oncogene; 2008 Mar 13; 27(12):1767-78. PubMed ID: 17891169
    [Abstract] [Full Text] [Related]

  • 3. [ITF-2357 on inhibition myeloid leukemic cell lines cells proliferation in vitro and its mechanism].
    Yu WJ, Wang L, You LS, Mei C, Ma QL, Jin J.
    Zhonghua Xue Ye Xue Za Zhi; 2012 May 13; 33(5):366-70. PubMed ID: 22781793
    [Abstract] [Full Text] [Related]

  • 4. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
    Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P.
    Br J Haematol; 2010 May 13; 149(4):518-28. PubMed ID: 20201941
    [Abstract] [Full Text] [Related]

  • 5. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, Chauhan D, Podar K, Mitsiades C, Dang L, Munshi N, Richardson P, Schenkein D, Anderson KC.
    Clin Cancer Res; 2006 Oct 01; 12(19):5887-94. PubMed ID: 17020997
    [Abstract] [Full Text] [Related]

  • 6. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
    Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, Chen H, Li ZW, Berenson JR.
    Leuk Res; 2011 Mar 01; 35(3):373-9. PubMed ID: 20650529
    [Abstract] [Full Text] [Related]

  • 7. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R.
    Cancer Res; 2004 Sep 15; 64(18):6626-34. PubMed ID: 15374977
    [Abstract] [Full Text] [Related]

  • 8. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.
    Mithraprabhu S, Khong T, Jones SS, Spencer A.
    Br J Haematol; 2013 Aug 15; 162(4):559-62. PubMed ID: 23692150
    [No Abstract] [Full Text] [Related]

  • 9. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
    Baumann P, Junghanns C, Mandl-Weber S, Strobl S, Oduncu F, Schmidmaier R.
    Br J Haematol; 2012 Mar 15; 156(5):633-42. PubMed ID: 22211565
    [Abstract] [Full Text] [Related]

  • 10. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
    Heider U, Kaiser M, Sterz J, Zavrski I, Jakob C, Fleissner C, Eucker J, Possinger K, Sezer O.
    Eur J Haematol; 2006 Jan 15; 76(1):42-50. PubMed ID: 16343270
    [Abstract] [Full Text] [Related]

  • 11. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 12. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG, Pugliese M, Gargantini E, Grange C, Bussolati B, Asioli S, Bosco O, Poli R, Compagnone A, Bandino A, Mainini F, Fortunati N, Boccuzzi G.
    Int J Cancer; 2012 Feb 01; 130(3):694-704. PubMed ID: 21400508
    [Abstract] [Full Text] [Related]

  • 13. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
    Qi H, Ratnam M.
    Cancer Res; 2006 Jun 01; 66(11):5875-82. PubMed ID: 16740727
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice.
    Zorzoli A, Di Carlo E, Cocco C, Ognio E, Ribatti D, Ferretti E, Dufour C, Locatelli F, Montagna D, Airoldi I.
    Clin Cancer Res; 2012 Mar 15; 18(6):1630-40. PubMed ID: 22383738
    [Abstract] [Full Text] [Related]

  • 15. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL, Marampon F, Giusti I, Carosa E, Di Sante S, Ricevuto E, Dolo V, Tombolini V, Jannini EA, Festuccia C.
    Int J Oncol; 2012 Mar 15; 40(3):711-20. PubMed ID: 22134754
    [Abstract] [Full Text] [Related]

  • 16. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
    Hwang JJ, Kim YS, Kim MJ, Jang S, Lee JH, Choi J, Ro S, Hyun YL, Lee JS, Kim CS.
    Anticancer Drugs; 2009 Oct 15; 20(9):815-21. PubMed ID: 19644355
    [Abstract] [Full Text] [Related]

  • 17. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357.
    Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Göttlicher M, Gregor M, Lauer UM, Bitzer M.
    J Hepatol; 2005 Feb 15; 42(2):210-7. PubMed ID: 15664246
    [Abstract] [Full Text] [Related]

  • 18. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia.
    Hackanson B, Rimmele L, Benkißer M, Abdelkarim M, Fliegauf M, Jung M, Lübbert M.
    Leuk Res; 2012 Aug 15; 36(8):1055-62. PubMed ID: 22464548
    [Abstract] [Full Text] [Related]

  • 19. Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation.
    Ashwini N, Garg M, Mohan CD, Fuchs JE, Rangappa S, Anusha S, Swaroop TR, Rakesh KS, Kanojia D, Madan V, Bender A, Koeffler HP, Basappa, Rangappa KS.
    Bioorg Med Chem; 2015 Sep 15; 23(18):6157-65. PubMed ID: 26299825
    [Abstract] [Full Text] [Related]

  • 20. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A.
    Ninios YP, Sekeri-Pataryas KE, Sourlingas TG.
    Leuk Res; 2010 Jun 15; 34(6):786-92. PubMed ID: 19782399
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.